285 related articles for article (PubMed ID: 26040705)
21. The impact of sirolimus therapy on lesion size, clinical symptoms, and quality of life of patients with lymphatic anomalies.
Ozeki M; Nozawa A; Yasue S; Endo S; Asada R; Hashimoto H; Fukao T
Orphanet J Rare Dis; 2019 Jun; 14(1):141. PubMed ID: 31196128
[TBL] [Abstract][Full Text] [Related]
22. Sirolimus (Rapamycin) for Slow-Flow Malformations in Children: The Observational-Phase Randomized Clinical PERFORMUS Trial.
Maruani A; Tavernier E; Boccara O; Mazereeuw-Hautier J; Leducq S; Bessis D; Guibaud L; Vabres P; Carmignac V; Mallet S; Barbarot S; Chiaverini C; Droitcourt C; Bursztejn AC; Lengellé C; Woillard JB; Herbreteau D; Le Touze A; Joly A; Léauté-Labrèze C; Powell J; Bourgoin H; Gissot V; Giraudeau B; Morel B
JAMA Dermatol; 2021 Nov; 157(11):1289-1298. PubMed ID: 34524406
[TBL] [Abstract][Full Text] [Related]
23. Indications and Limitations of Sirolimus in the Treatment of Vascular Anomalies-Insights From a Retrospective Case Series.
Karastaneva A; Gasparella P; Tschauner S; Crazzolara R; Kropshofer G; Modl M; Pfleger A; Burmas A; Pocivalnik M; Ulreich R; Zenz W; Schwinger W; Beqo BP; Urban C; Haxhija EQ; Lackner H; Benesch M
Front Pediatr; 2022; 10():857436. PubMed ID: 35676905
[TBL] [Abstract][Full Text] [Related]
24. Effects of sirolimus in the treatment of unresectable infantile hemangioma and vascular malformations in children: A single-center experience.
Cho YJ; Kwon H; Kwon YJ; Kim SC; Kim DY; Namgoong JM
J Vasc Surg Venous Lymphat Disord; 2021 Nov; 9(6):1488-1494. PubMed ID: 33836285
[TBL] [Abstract][Full Text] [Related]
25. Sirolimus as initial therapy for kaposiform hemangioendothelioma and tufted angioma.
Wang H; Guo X; Duan Y; Zheng B; Gao Y
Pediatr Dermatol; 2018 Sep; 35(5):635-638. PubMed ID: 29999213
[TBL] [Abstract][Full Text] [Related]
26. Sirolimus in the treatment of kaposiform lymphangiomatosis.
Zhou J; Yang K; Chen S; Ji Y
Orphanet J Rare Dis; 2021 Jun; 16(1):260. PubMed ID: 34103076
[TBL] [Abstract][Full Text] [Related]
27. Medical management of vascular anomalies of the head and neck.
Léauté-Labrèze C
J Oral Pathol Med; 2022 Nov; 51(10):837-843. PubMed ID: 35668029
[TBL] [Abstract][Full Text] [Related]
28. [A new treatment for vascular anomalies: Six cases treated with rapamycin].
Thirion S; Jamblin P; Demarche M; Boon L; Thiry A; Hoyoux C
Arch Pediatr; 2017 Jul; 24(7):600-606. PubMed ID: 28595829
[TBL] [Abstract][Full Text] [Related]
29. Successful Treatment of a Complex Vascular Malformation With Sirolimus and Surgical Resection.
Goldenberg DC; Carvas M; Adams D; Giannotti M; Gemperli R
J Pediatr Hematol Oncol; 2017 May; 39(4):e191-e195. PubMed ID: 27820120
[TBL] [Abstract][Full Text] [Related]
30. A narrative review of the role of sirolimus in the treatment of congenital vascular malformations.
Geeurickx M; Labarque V
J Vasc Surg Venous Lymphat Disord; 2021 Sep; 9(5):1321-1333. PubMed ID: 33737259
[TBL] [Abstract][Full Text] [Related]
31. Menstrual disorders associated with sirolimus treatment.
Triana P; López-Gutierrez JC
Pediatr Blood Cancer; 2021 Mar; 68(3):e28867. PubMed ID: 33369022
[TBL] [Abstract][Full Text] [Related]
32. Treatment of childhood kaposiform hemangioendothelioma with sirolimus.
Blatt J; Stavas J; Moats-Staats B; Woosley J; Morrell DS
Pediatr Blood Cancer; 2010 Dec; 55(7):1396-8. PubMed ID: 20730884
[TBL] [Abstract][Full Text] [Related]
33. Antiproliferative therapy with sirolimus and propranolol for congenital vascular anomalies in newborns (Case reports).
Cîrstoveanu C; Bizubac AM; Mustea C; Manolache Ș; Istrate-Bârzan A; Sfrijan D; Marcu V; Iozsa DA; Spătaru RI
Exp Ther Med; 2021 Oct; 22(4):1097. PubMed ID: 34504551
[TBL] [Abstract][Full Text] [Related]
34. Oral and Topical Sirolimus for Vascular Anomalies: A Multicentre Study and Review.
Sandbank S; Molho-Pessach V; Farkas A; Barzilai A; Greenberger S
Acta Derm Venereol; 2019 Oct; 99(11):990-996. PubMed ID: 31304557
[TBL] [Abstract][Full Text] [Related]
35. Oral rapamycin: an alternative in children with complicated vascular abnormalities.
Gómez Sánchez A; Redondo Sedano JV; Pérez Alonso V; Martí Carrera ME; Baro Fernández M; Palencia Pérez SI; Gallego Herrero MC; Gómez Fraile A; Delgado Muñoz MD
Cir Pediatr; 2020 Oct; 33(4):183-187. PubMed ID: 33016658
[TBL] [Abstract][Full Text] [Related]
36. No Association of Sirolimus with Wound Complications in Children With Vascular Anomalies.
Mehl SC; Whitlock RS; Ortega RM; Creden S; Iacobas I; Maricevich RS; Rosenberg TL; Rialon KL
J Pediatr Surg; 2023 Aug; 58(8):1555-1559. PubMed ID: 36599792
[TBL] [Abstract][Full Text] [Related]
37. [Clinicopathologic study of pediatric vascular anomalies: a report of 117 cases].
Niu HL; Zhou SY; Lin QQ; Yi P; Wang FH; Gao Q; Chen ZR; Xia JQ; Zheng HC; Zeng RX
Zhonghua Bing Li Xue Za Zhi; 2016 Apr; 45(4):252-7. PubMed ID: 27033389
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of oral sirolimus for high-flow vascular malformations in real clinical practice.
Durán-Romero AJ; Hernández-Rodríguez JC; Ortiz-Álvarez J; Domínguez-Cruz JJ; Monserrat-García MT; Conejo-Mir Sánchez J; Bernabeu-Wittel J
Clin Exp Dermatol; 2022 Jan; 47(1):57-62. PubMed ID: 34240451
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and Safety of Sirolimus in the Treatment of Complicated Vascular Anomalies.
Adams DM; Trenor CC; Hammill AM; Vinks AA; Patel MN; Chaudry G; Wentzel MS; Mobberley-Schuman PS; Campbell LM; Brookbank C; Gupta A; Chute C; Eile J; McKenna J; Merrow AC; Fei L; Hornung L; Seid M; Dasgupta AR; Dickie BH; Elluru RG; Lucky AW; Weiss B; Azizkhan RG
Pediatrics; 2016 Feb; 137(2):e20153257. PubMed ID: 26783326
[TBL] [Abstract][Full Text] [Related]
40. A Case Report of 2 Sirolimus-Related Deaths Among Infants With Kaposiform Hemangioendotheliomas.
Ying H; Qiao C; Yang X; Lin X
Pediatrics; 2018 Apr; 141(Suppl 5):S425-S429. PubMed ID: 29610165
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
